- Home
- DJCO vs OCS Comparison
DJCO vs OCS Comparison
Compare DJCO & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DJCO
- OCS
- Stock Information
- Founded
- DJCO 1987
- OCS 2003
- Country
- DJCO United States
- OCS Switzerland
- Employees
- DJCO N/A
- OCS N/A
- Industry
- DJCO Newspapers/Magazines
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- DJCO Consumer Discretionary
- OCS Health Care
- Exchange
- DJCO Nasdaq
- OCS Nasdaq
- Market Cap
- DJCO 812.5M
- OCS 706.3M
- IPO Year
- DJCO N/A
- OCS N/A
- Fundamental
- Price
- DJCO $548.99
- OCS $14.14
- Analyst Decision
- DJCO
- OCS Strong Buy
- Analyst Count
- DJCO 0
- OCS 5
- Target Price
- DJCO N/A
- OCS $29.20
- AVG Volume (30 Days)
- DJCO 13.1K
- OCS 73.4K
- Earning Date
- DJCO 12-26-2024
- OCS 11-07-2024
- Dividend Yield
- DJCO N/A
- OCS N/A
- EPS Growth
- DJCO N/A
- OCS N/A
- EPS
- DJCO 32.61
- OCS N/A
- Revenue
- DJCO $71,608,000.00
- OCS $1,027,571.00
- Revenue This Year
- DJCO N/A
- OCS $4.38
- Revenue Next Year
- DJCO N/A
- OCS $905.09
- P/E Ratio
- DJCO $16.84
- OCS N/A
- Revenue Growth
- DJCO 10.74
- OCS N/A
- 52 Week Low
- DJCO $309.22
- OCS $9.60
- 52 Week High
- DJCO $602.00
- OCS $18.00
- Technical
- Relative Strength Index (RSI)
- DJCO 57.72
- OCS 37.01
- Support Level
- DJCO $565.00
- OCS $16.44
- Resistance Level
- DJCO $602.00
- OCS $18.00
- Average True Range (ATR)
- DJCO 17.14
- OCS 0.68
- MACD
- DJCO 3.30
- OCS -0.46
- Stochastic Oscillator
- DJCO 55.60
- OCS 3.50
About DJCO Daily Journal Corp. (S.C.)
Daily Journal Corp publishes newspapers and websites covering California and Arizona and produces several specialized information services. The company operates in two segments: Traditional business and Journal Technologies. It also serves as a newspaper representative specializing in public notice advertising. The majority of revenue is generated from the Journal Technologies segment.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.